Chief Commercial Officer, Immune Medicine · Adaptive Biotechnologies Corp (ADPT)

Sharon Benzeno

FY2022 is the first fiscal year CompBrief holds for Sharon Benzeno as a named executive officer of Adaptive Biotechnologies; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$3,237,784

Salary $456,250Stock awards $999,996

5th of 7 named executive officers at Adaptive Biotechnologies by FY2022 total.

7 named officers on file for Adaptive Biotechnologies, FY2022

Sharon Benzeno’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 1 equity grant, each cited to its filing
  • ADPT’s disclosed peer group of 20 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Adaptive Biotechnologies’s whole pay program stands against its peers

  • Adaptive Biotechnologies’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ADPT→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 28, 2023 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Sharon Benzeno’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Sharon Benzeno compensation by year

Adaptive Biotechnologies Summary Compensation Table · the one fiscal year held
In US dollars, as Adaptive Biotechnologies reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022
Salary$456,250
Bonus$0
Stock awards$999,996
Option awards$1,566,497
Non-equity incentive$210,781
Pension and deferred compensation$0
All other$4,260
Total$3,237,784

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Adaptive Biotechnologies Corp DEF 14A filed April 28, 2023, accession 0001193125-23-126845, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Adaptive Biotechnologies Corp filed document, accession 0001193125-23-126845. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2023.

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
RSU132,979$797,209—
RSU99,735$597,911—
RSU41,186$246,910—
RSU5,724$34,315—
Option112,247—$8.46
Option3,578—$43.68
Option64,354—$12.14
Option199,549—$3.99

Per the Outstanding Equity Awards at Fiscal Year-End table in Adaptive Biotechnologies Corp's FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

47 Form 4 lines since the FY2022 proxy (filed April 28, 2023)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-06-29Sale10b5-1154,768$21.14221,278
2026-06-29Exercise or conversion derivative10b5-124,944$0.0037,416
2026-06-29Exercise or conversion10b5-11,837$12.14274,588
2026-06-29Exercise or conversion derivative10b5-124,944$0.0087,303
2026-06-29Exercise or conversion10b5-151,570$8.12376,046
2026-06-29Exercise or conversion10b5-124,944$8.46299,532
2026-06-29Exercise or conversion10b5-124,944$3.99324,476
2026-06-29Exercise or conversion derivative10b5-151,570$0.00113,457

The 8 most recent of 47 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Adaptive Biotechnologies’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
Chad RobinsChief Executive Officer$8,853,328
Harlan RobinsChief Scientific Officer$8,459,087
Julie RubinsteinPresident and Chief Operating Officer$6,535,078
Tycho PetersonChief Financial Officer$5,938,257
Sharon Benzeno · this pageChief Commercial Officer, Immune Medicine$3,237,784
Kyle PiskelInterim Chief Financial Officer$1,659,147
Chad CohenFormer Chief Financial Officer$72,221

The full Adaptive Biotechnologies compensation record

free company brief

This page is one person within Adaptive Biotechnologies's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Adaptive Biotechnologies proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Adaptive Biotechnologies's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Sharon Benzeno's compensation dossier · One-time report. No refunds.